Phathom Pharmaceuticals, Inc. PHAT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s additional paid-in capital?
- Phathom Pharmaceuticals, Inc. (PHAT) reported additional paid-in capital of $1.18B in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s additional paid-in capital increased by 15.6% year-over-year, from $1.02B to $1.18B.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 12.5% compound annual growth rate (CAGR), from $579.76M to $1.05B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.